01/07/2025 HanchorBio and Henlius signed a ~$200M licensing deal for HanchorBio's HCB101 (Ref) HanchorBio and Shanghai Henlius Biotech signed an out-licensing agreement which granted Henlius the exclusive development and commercialization rights to HanchorBio's HCB101 (SIRPα-IgG4 Fc fusion protein) across Greater China (including Mainland China, Hong Kong, and Macau), key Southeast Asian countries, as well as all countries in the Middle East and North Africa (MENA) Under the